Login to Your Account

Other News To Note

Wednesday, January 4, 2012
• TiGenix NV, of Leuven, Belgium, and its subsidiary Cellerix SA, of Tres Cantos, Spain, will receive about $3.8 million from the European Seventh Framework Programme to support the development of their Cx611 program of allogeneic expanded adipose-derived stem cells to treat rheumatoid arthritis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription